Glucocorticoid receptor antagonists - Pipeline Insight, 2022
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Glucocorticoid Receptor Antagonist - Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Glucocorticoid Receptor Antagonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Glucocorticoid Receptor Antagonist: Overview
Glucocorticoids (GCs) are adrenal hormones involved in the stress response, regulating processes such as immune function and metabolism. Glucocorticoids mediate numerous essential processes in the human body via binding to the glucocorticoid receptor (GR). Excessive GR signaling can cause disease, and GR antagonists can be used to treat many symptoms of glucocorticoid-induced pathology.
Function – Glucocorticoid Receptor (GR, or GCR) also known as NR3C1 (nuclear receptor subfamily 3, group C, member 1) is the receptor to which cortisol and other glucocorticoids bind. When the glucocorticoid receptor binds to glucocorticoids, its primary mechanism of action is the regulation of gene transcription. The unbound receptor resides in the cytosol of the cell. After the receptor is bound to glucocorticoid, the receptor-glucorticoid complex can take either of two paths. The activated GR complex up-regulates the expression of anti-inflammatory proteins in the nucleus or represses the expression of pro-inflammatory proteins in the cytosol by preventing the translocation of other transcription factors from the cytosol into the nucleus.
Glucocorticoid Receptor Antagonist- Increased cortisol levels have been observed in patients suffering from a number of metabolic and psychiatric disorders. Glucocorticoid Receptor Antagonist which block cortisol effects might have a benefit in both the diagnosis and treatment of these disorders.
Glucocorticoid Receptor Antagonist Emerging Drugs Chapters
This segment of the Glucocorticoid Receptor Antagonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Glucocorticoid Receptor Antagonist Emerging Drugs
Further product details are provided in the report……..
Glucocorticoid Receptor Antagonist: Therapeutic Assessment
This segment of the report provides insights about the different Glucocorticoid Receptor Antagonist drugs segregated based on following parameters that define the scope of the report, such as:
Glucocorticoid Receptor Antagonist: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Glucocorticoid Receptor Antagonist therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Glucocorticoid Receptor Antagonist drugs.
Report Highlights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Glucocorticoid Receptor Antagonist - Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Glucocorticoid Receptor Antagonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Glucocorticoid Receptor Antagonist: Overview
Glucocorticoids (GCs) are adrenal hormones involved in the stress response, regulating processes such as immune function and metabolism. Glucocorticoids mediate numerous essential processes in the human body via binding to the glucocorticoid receptor (GR). Excessive GR signaling can cause disease, and GR antagonists can be used to treat many symptoms of glucocorticoid-induced pathology.
Function – Glucocorticoid Receptor (GR, or GCR) also known as NR3C1 (nuclear receptor subfamily 3, group C, member 1) is the receptor to which cortisol and other glucocorticoids bind. When the glucocorticoid receptor binds to glucocorticoids, its primary mechanism of action is the regulation of gene transcription. The unbound receptor resides in the cytosol of the cell. After the receptor is bound to glucocorticoid, the receptor-glucorticoid complex can take either of two paths. The activated GR complex up-regulates the expression of anti-inflammatory proteins in the nucleus or represses the expression of pro-inflammatory proteins in the cytosol by preventing the translocation of other transcription factors from the cytosol into the nucleus.
Glucocorticoid Receptor Antagonist- Increased cortisol levels have been observed in patients suffering from a number of metabolic and psychiatric disorders. Glucocorticoid Receptor Antagonist which block cortisol effects might have a benefit in both the diagnosis and treatment of these disorders.
Glucocorticoid Receptor Antagonist Emerging Drugs Chapters
This segment of the Glucocorticoid Receptor Antagonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Glucocorticoid Receptor Antagonist Emerging Drugs
- Relacorilant: Corcept Therapeutics
- Miricorilant: Corcept Therapeutics
Further product details are provided in the report……..
Glucocorticoid Receptor Antagonist: Therapeutic Assessment
This segment of the report provides insights about the different Glucocorticoid Receptor Antagonist drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Glucocorticoid Receptor Antagonist
- Phases
- Late-stage products (Phase III )
- Mid-stage products (Phase II )
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intravenous
- Intramuscular
- Oral
- Parenteral
- Subcutaneous
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Glucocorticoid Receptor Antagonist: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Glucocorticoid Receptor Antagonist therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Glucocorticoid Receptor Antagonist drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Glucocorticoid Receptor Antagonist R&D.
- The therapies under development are focused on novel approaches for Glucocorticoid Receptor Antagonist.
- Glucocorticoid Receptor Antagonist Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Glucocorticoid Receptor Antagonist drugs?
- How many Glucocorticoid Receptor Antagonist drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Glucocorticoid Receptor Antagonist?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Glucocorticoid Receptor Antagonist therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Glucocorticoid Receptor Antagonist and their status?
- What are the key designations that have been granted to the emerging drugs?
Introduction
Executive Summary
Glucocorticoid Receptor Antagonist: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Glucocorticoid Receptor Antagonist – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Glucocorticoid Receptor Antagonist companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Glucocorticoid Receptor Antagonist Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Relacorilant: Corcept Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Miricorilant: Corcept Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
ORIC 101: ORIC Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Glucocorticoid Receptor Antagonist Key Companies
Glucocorticoid Receptor Antagonist Key Products
Glucocorticoid Receptor Antagonist- Unmet Needs
Glucocorticoid Receptor Antagonist- Market Drivers and Barriers
Glucocorticoid Receptor Antagonist- Future Perspectives and Conclusion
Glucocorticoid Receptor Antagonist Analyst Views
Glucocorticoid Receptor Antagonist Key Companies
Appendix
Executive Summary
Glucocorticoid Receptor Antagonist: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Glucocorticoid Receptor Antagonist – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Glucocorticoid Receptor Antagonist companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Glucocorticoid Receptor Antagonist Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Relacorilant: Corcept Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Miricorilant: Corcept Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
ORIC 101: ORIC Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Glucocorticoid Receptor Antagonist Key Companies
Glucocorticoid Receptor Antagonist Key Products
Glucocorticoid Receptor Antagonist- Unmet Needs
Glucocorticoid Receptor Antagonist- Market Drivers and Barriers
Glucocorticoid Receptor Antagonist- Future Perspectives and Conclusion
Glucocorticoid Receptor Antagonist Analyst Views
Glucocorticoid Receptor Antagonist Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Glucocorticoid receptor antagonists
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Glucocorticoid receptor antagonists
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Glucocorticoid receptor antagonists
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Glucocorticoid receptor antagonists
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products